GlassScriptPhysician profile
Peter A Okwuasaba
NPI 1497803209
$14,876.14
in general payments reported to CMS, 2019-2025
26 companies · $762 in 2025
The $762 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,925 · 2020: $1,583 · 2021: $1,814 · 2022: $1,454 · 2023: $1,183 · 2024: $1,155 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.57 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,857.39 | 2019-2020 | |
| Viiv Healthcare Company | $2,362.20 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $1,944.04 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $1,191.41 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $728.83 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $685.55 | 2019-2025 | Nuzyra |
| Insmed, INC. | $462.65 | 2019-2025 | Arikayce |
| Emd Serono, INC. | $379.40 | 2023-2025 | Serostim |
| Melinta Therapeutics, LLC | $320.50 | 2019-2022 | |
| Janssen Biotech, INC. | $284.05 | 2019-2023 | Symtuza |
| Shionogi INC | $250.85 | 2022-2025 | Fetroja |
| Astellas Pharma US INC | $199.18 | 2024 | Cresemba |
| La Jolla Pharmaceutical Company | $196.40 | 2020-2023 | Xerava |
| Ferring Pharmaceuticals INC. | $170.80 | 2023 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $156.85 | 2019-2025 | Vibativ |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $154.95 | 2021-2022 | |
| Napo Pharmaceuticals INC | $118.91 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $115.41 | 2020-2021 | |
| Vyera Pharmaceuticals, LLC | $73.55 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $55.63 | 2020 | |
| Angiodynamics, INC. | $45.72 | 2019 | |
| Aimmune Therapeutics, INC. | $38.94 | 2024-2025 | Vowst |
| Cormedix INC. | $27.78 | 2025 | Defencath |
| T2 Biosystems, INC. | $20.95 | 2019 | |
| Electromed, INC. | $18.18 | 2021 | |
| Pfizer INC. | $16.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Okwuasaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.